Tumor burden in ACY738/anti-PD-L1 group was decreased compared to anti-PD-L1 group (Figure 5B) in peripheral blood, and both ACY738/anti-PD-1 and ACY738/anti-PD-L1 groups exhibited decreased tumor burden compared to anti-PD-1 or anti-PD-L1 groups, respectively, in spleen tissue (Figure S5A), suggesting that these combinations elicited a beneficial antitumor effect. Here, CD274 is linked to neoplasm.